Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members
Open accessThe DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index; 19 of the 58 sources its claims cite were checked for support.
Abstract
We examined the role of hepatic heparan sulfate in triglyceride-rich lipoprotein metabolism by inactivating the biosynthetic gene GlcNAc N-deacetylase/N-sulfotransferase 1 (Ndst1) in hepatocytes using the Cre-loxP system, which resulted in an approximately 50% reduction in sulfation of liver heparan sulfate. Mice were viable and healthy, but they accumulated triglyceride-rich lipoprotein particles containing apoB-100, apoB-48, apoE, and apoCI-IV. Compounding the mutation with LDL receptor deficiency caused enhanced accumulation of both cholesterol- and triglyceride-rich particles compared with mice lacking only LDL receptors, suggesting that heparan sulfate participates in the clearance of cholesterol-rich lipoproteins as well. Mutant mice synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduction in hepatic VLDL uptake. Retinyl ester excursion studies revealed that clearance of intestinally derived lipoproteins also depended on hepatocyte heparan sulfate. These findings show that under normal physiological conditions, hepatic heparan sulfate proteoglycans play a crucial role in the clearance of both intestinally derived and hepatic lipoprotein particles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 22 Not checked · 102 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Total plasma cholesterol was not affected (80.1 ± 10.1 mg/dl versus 81.4 ± 9.1; n = 20; P = 0.68) (Figure 2B), which contrasts the phenotype of LDLR and LRP mutant mice (15,49).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Ndst1 f/f AlbCre + mice accumulate TRLs.
What the sources say
- Not checked — no full text of the sourcecites [15] Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695. source
- Supportedcites [49] Ishibashi, S., et al. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene deliv- ery. J. Clin. Invest. 92:883-893. source
The citation supports the contrast with LDLR-mutant mice, not the citing authors’ 80.1 versus 81.4 mg/dl result. In the Disrupted Allele Wildtype Allele section (Table I; page not provided), the source reports that LDLR-mutant mice have elevated total plasma cholesterol compared with wild-type littermates. (LLM, conf=0.90)
plainn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 2-O-sulfation of uronic acids (ΔUA2S-GlcNS and ΔUA2S-GlcNS6S) showed a larger decrease (15% in controls to 3% in the mutant), consistent with previous analyses of HS from mice containing systemic inactivation of Ndst1 (43,44).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Hepatocyte-specific Ndst1 gene disruption alters HS synthesis in liver.
What the sources say
- Supportedcites [43] Grobe, K., et al. 2005. Cerebral hypoplasia and cra- niofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development. 132:3777-3786. source
The citation supports the stated consistency with earlier Ndst1 analyses, not the citing study’s exact 15%-to-3% figures. The source’s Results and Table 1 report a marked decrease in 2-O-sulfated disaccharides in Ndst1 mutant embryos, from 9.7% in wild type to 3.8% in mutants. (LLM, conf=0.92)
- Partly supportedcites [44] Ledin, J., et al. 2004. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279:42732-42741. sourceExperimental — accuracy not yet measured
The Results (page unavailable; Table II and Fig. 6A) report that all species of 2-O-sulfated disaccharides decreased in NDST-1-deficient tissues, supporting the direction of the claim. The passages do not give the stated change from 15% in controls to 3% in the mutant, so that magnitude is not verified by our copy. (LLM, conf=0.83)
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Partly supportedcites [38] Mann, W.A., et al. 1995. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). J. Clin. Invest. 96:1100-1107. sourceExperimental — accuracy not yet measured
The Results report that apoE-1 (Lys146→Glu) bound heparin at 10% of the apoE-3 level, and the Abstract associates this mutant with type III hyperlipoproteinemia. The Discussion uses heparin as a model for cell-surface proteoglycans, but the paper does not directly show reduced HS binding or establish that several rare alleles cause severe hyperlipoproteinemia. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [39] Mann, W.A., et al. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associ- ated type III hyperlipoproteinemia. J. Lipid Res. 36:517-525. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [40] Lutz, E.P., et al. 2001. Heparin-binding defective lipoprotein lipase is unstable and causes abnor- malities in lipid delivery to tissues. J. Clin. Invest. 107:1183-1192. source
The Abstract reports that mice expressing LpL with reduced heparin binding had defective targeting of lipids to tissues, with decreased uptake in muscle and increased uptake in kidneys. The Discussion likewise reports altered tissue lipid uptake compared with mice expressing nonmutated LpL. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clearance of TRLs occurs normally in humans, WHHL rabbits, and mice deficient in LDLR (11)(12)(13).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [11] Rubinsztein, D.C., et al. 1990. Chylomicron rem- nant clearance from the plasma is normal in famil- ial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312. source
The Discussion (p. 1311) reports normal chylomicron-remnant clearance in human familial hypercholesterolemia subjects with varying degrees of LDL-receptor deficiency. In this three-citation sentence, that human finding is the part supported by this source; the rabbit and mouse findings are not attributed to it individually. (LLM, conf=0.92)
- Supportedcites [12] Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism geneti- cally distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:3623-3627. source
The indexed paper reports that LDL-receptor-deficient WHHL rabbits cleared chylomicrons from plasma at a normal rate, with radiolabeled components removed at comparable rates in WHHL and normal rabbits (section and page not supplied). This paper supports the WHHL-rabbit portion of the sentence; the human and mouse portions have separate citations. (LLM, conf=0.93)
- Partly supportedcites [13] Ishibashi, S., et al. 1996. Role of the low den- sity lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quan- titative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427. sourceExperimental — accuracy not yet measured
The Introduction reports little detectable remnant accumulation in LDLR-deficient humans and rabbits, and the Results report prompt clearance of injected remnants in LDLR-deficient mice. But the Results also show a fourfold larger retinyl-ester excursion in those mice after a fat load, so the unqualified claim of normal clearance in mice overstates the paper's findings. The passages supplied do not include page numbers. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
75 more claims · 4 with their cited sources checked
Create a free account to see all 139 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 39
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TRLs arising from LPL-mediated lipolysis are cleared by multiple hepatic receptors, including LDL receptor (LDLR), LDLR-related protein 1 (LRP1), and syndecan-1 (SDC), the predominant hepatic heparin sulfate proteoglycan (HSPG) (Bishop et al., 2008; Foley et al., 2013; MacArthur et al., 2007; Stanford et al., 2009).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as MacArthur et al., 2007
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that both Ldlr–/– and Sdc1–/– mice both accumulate plasma triglycerides”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954 -955).”
From Biological roles of glycans (2017) · cites this paper as [954]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, we showed previously that compounding Ldlr–/– with Ndst1f/fAlbCre+ mice causes an additive accumulation of plasma triglycerides and prolonged the delay in postprandial clearance manifested by each individual mutant (9).”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A modified uronic acid carbazole reaction
Bitter, T., & Muir, H. M. (1962) · Analytical Biochemistry · doi:10.1016/0003-2697(62)90095-7 · Cited by 6,274
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
An Automated Multidimensional Protein Identification Technology for Shotgun Proteomics
Wolters, D. A., Washburn, M. P., & Yates, J. R. (2001) · Analytical Chemistry · doi:10.1021/ac010617e · Cited by 1,819
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Self-citationIshibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Research works printed but not linked: 2
- Belting, M. 2003. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28:145-151. · DOI · Paper page
- Iverius, P., and Ostlund-Lindqvist, A. 1986. Prepa- ration, characterization, and measurement of lipo- protein lipase. In Methods in enzymology. J.J. Albers and J.P. Segrest, editors. Academic Press. Orlando, Florida, USA. 691-704.
Cited by
Items 201–224 of 224
Heparan sulphate compounds regulate cholesterol metabolism in neurodegenerative disease models
Heathcott, R. W. (2015) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148107
(2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328303e27e
Program Overview * Conference Program * Conference Posters * Conference Abstracts * Author Index
Schnaar, R., Paulson, J. C., Macauley, M. S., Nycholat, C., Pfrengle, F., Rademacher, C., Mahan, A. E., Dionne, K., Suscovich, T. J., Alter, G., et al. (2012) · Glycobiology · doi:10.1093/glycob/cws127
Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins
Fazio, S., & Linton, M. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00002-5 · Cited by 2
Strickland, D. K., & Cooper, J. M. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322058
Heparan sulfate chains in hepatocellular carcinoma
Guyot, E. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf023
“…HS chain characteristics are crucial in this role—using different genetically modified mouse models (deficient in Ext1 and HS2ST for instance) [104–106] Transgenic mice overexpressing human heparanase show reduced hepatic clearance of postprandial lipoproteins and higher levels of serum…”
Yu, C.-J., Pessentheiner, A. R., Liu, S., Wax, S., Maciej-Hulme, M. L., Painter, C. D., Ramms, B., Sandoval, D. R., Quach, A., DeForest, N., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102267 · Cited by 2
“…+ mice, Fgfr1 f/f Adiponectin-Cre + mice, and Ndst1 f/f Adiponectin-Cre + mice were generated by crossing the Ext1 f/ f (gifted by Dr. Yu Yamaguchi), Fgfr1c (The Jackson Laboratory), and Ndst1 f/f (gifted by Dr. Jeffrey Esko) mice to AdipoQ-Cre transgenic mice (The Jackson laboratory) [15,16].”
Lin, L. (2023) · eScholarship (California Digital Library)
Hanse, M. (2011) · theses.fr (ABES) · doi:10.70675/0a6de16dz1681z48b0zada8zd0b0d5d3e6b9 · Cited by 1
Lebreton, A. (2012) · theses.fr (ABES) · doi:10.70675/8f91002ez1eacz42fcz8001z2b72762a2b71
Rôle de l'apoliprotéine E dans le cycle du virus de l'hépatite C
Lefèvre, M. (2014) · theses.fr (ABES) · doi:10.70675/f91c33acz493dz464bza628zd78da966c293
Importance des glycosaminoglycanes de surface dans les phénomènes inflammatoires liés au cancer
Martinez, P. (2014) · theses.fr (ABES) · doi:10.70675/d8d46778ze3baz4df0z9270z4a2656f165d0 · Cited by 1
Characterization of Hepatitis C Virus interaction with heparan sulfate proteoglycans
Xu, Y. (2014) · theses.fr (ABES) · doi:10.70675/b8c9dc27z15cfz4921zad5czee757d47d341
“NDST1-deleted hepatocytes displayed a defective clearance of TRL-rich lipoproteins, suggesting that the Nsulfation of HS is very important for its function (MacArthur et al., 2007).”
Regulation and role of syndecan-1 in thoracic aneurysm s and atherosclerosis
Zalghout, S. (2022) · theses.fr (ABES) · doi:10.70675/91e6e4cfz258cz45c4zad26z99cd2a9b0403
Heparan Sulfate 2-O-Sulfotransferase (HS2ST)
Habuchi, H. (2014) · Springer eBooks · doi:10.1007/978-4-431-54240-7_67
Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E., & Strickland, D. K. (2008) · Physiological Reviews · doi:10.1152/physrev.00033.2007 · Cited by 669
“triglyceride-rich lipoprotein particles (145), revealing that”
Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism
Bishop, J. R., Stanford, K. I., & Esko, J. D. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282feec2d · Cited by 49
Self-citation
Metadata
- Authors
- MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D.
- Affiliations
- University of California San Diego (US)
- Cornell University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-01-02
- Volume
- 117
- Issue
- 1
- Pages
- 153-164
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1716206
- OpenAlex
- W2157280645
- Cited by
- 216
- References
- 91
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 14 · 2015: 12 · 2014: 17 · 2013: 14 · 2012: 11
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institutes of Health (HL57345, GM33063)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (HL 57345, P50HL056989, P01HL057345, HL-56989)
- National Institute of General Medical Sciences (R01GM033063, R37GM033063, GM-33063)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- heparan sulfate proteoglycans, triglyceride-rich lipoproteins, lipoprotein clearance, NDST1, LDL receptor, hepatic lipoprotein metabolism, apolipoproteins
- MeSH terms
- Apolipoproteins E, Humans, Lipoproteins, Liver, Receptors, LDL, Triglycerides, Hypertriglyceridemia, Fibroblast Growth Factor 2, Heparan Sulfate Proteoglycans, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.